35% or 17%), the difference in PFS did not reach statistical significance ( 82 ).
← all excerpts
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.
1
—
—
35% or 17%), the difference in PFS did not reach statistical significance ( 82 ).